

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT CE MARK APPROVAL OF VITAFLOW LIBERTY®

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement and product registration progress of the Group.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) is pleased to announce that on April 24, 2024, the Group’s self-developed VitaFlow Liberty® transcatheter aortic valve and retrievable delivery system (“**VitaFlow Liberty®**”) received the CE Mark (certification mark that indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area) approval.

VitaFlow Liberty® is the Group’s self-developed second generation transcatheter aortic valve implantation product. Up to now, VitaFlow Liberty® and its procedural accessories as supporting supply, have entered nearly 600 hospitals in China and nearly a hundred hospitals in Argentina, Colombia, Thailand, Russia and Indonesia cumulatively.

The CE Mark approval of VitaFlow Liberty® signifies that its innovative R&D (research and development) design and excellent clinical performance have reached the international level, which is an important milestone in the Company’s development progress and global strategic layout, and also provides prerequisite for the Group to enter the European market for the interventional treatment of structural heart diseases. It will further expand the

Group's sources of sales revenue and enhance its comprehensive competitiveness, enabling to provide universal access to state-of-the-art total solutions from China to more physicians and patients around the world, and will also help promote innovation and development in the global field of interventional therapy for valvular heart disease.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, April 25, 2024

As of the date of this announcement, the executive Directors are Mr. Jeffrey R Lindstrom, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.